Press Releases

Ozenoxacin, a novel bactericidal non-fluorinated quinolone that successfully completed a first phase III clinical trial in adult and paediatric patients with impetigo, is available from Ferrer for licensing and commercialisation Ferrer, a privately-held Spanish pharmaceutical company,...

There are 5 million persons suffering from asthma in Great Britain and despite medication, half a million of these persons have symptoms which limit their daily life. In some serious cases, the asthma develop may into a life-threatening condition....

The global market for Point of Care diagnostics is set to sharply increase by 2018 and Europe’s market is becoming increasingly competitive due to its low barriers of entry. Based on this information SMi is proud...

As of January 2014, the EMA lifted the restriction on providing fee reductions to large companies developing new orphan drugs and the Early Access to Medicines Scheme was introduced. Key implementation of this will be a factor into further...

Provence Technologies acquires SynprosisThe acquisition strengthens Provence Technologies’ expertise in its core business of therapeutic chemistryProvence Technologies Group, a specialist fine chemistry research group, today announces its acquisition of Synprosis, a company specialized in the chemical synthesis of peptides...

Disruptive Innovation – Health – Funding | Immunotherapies – Healthy AgeingOnly one week left to join us in Lyon to meet the key international players in health care and life sciences, including representatives from academia, the public and private...

The Orphan Drugs Market is set to Rise as a Result of Pharma Companies now Looking to Orphan Drugs as an Essential Revenue Stream in 2014   As of January 2014, the EMA lifted the restriction...